After Moderna announced in early September that it started submitting data regarding its booster shot to the FDA, Johnson & Johnson followed the suit, announcing it’ll seek authorization for a booster shot this week, The New York Times reports.
As concerns rise regarding the effectiveness of J&J single-shot COVID-19 vaccine compared to other jabs and, the pharma company is the last of the three federally authorized vaccine providers to apply for booster shots to offer more protection at least to the older adults and people in high-risk groups.
The company claimed in September that its research showed its booster provides 94% protection of COVID-19.
As announced on Friday, the Food and Drug Administration’s (FDA expert advisory committee will discuss booster shots for Johnson & Johnson’s and Moderna’s vaccines during its meetings on Oct. 14 and 15.
The NYT noted that advisory committee’s meeting scheduling even before J&J submitted an application for authorization points to the urgency in which the FDA is looking to get approval for booster shots after it authorized last month booster shots for Pfizer’s vaccine for older than 65 years and for people at high risk of severe disease.
According to Centers for Disease Control and Prevention’s (CDS) study released late last month, J&J’s vaccine is the least effective in preventing hospitalizations for COVID-19 with success rate of 71%, compared to Pfizer’s jab with 88% and Moderna’s jab with success rate of 93%.